Dual Regulation of Post-Translational Modification of Proteins: Bottlenecks and Breakthroughs in NK Cell Therapy for Glioblastoma.

PAK4 functions as an immune suppressor by reprogramming the phosphatidylcholine metabolism of CD8 + T cells within the glioblastoma tumor microenvironment.

RFC4 drives temozolomide resistance in glioblastoma by activating STK38-BECN1-dependent autophagy.

Deciphering the STAT3-PXN positive feedback loop in GBM, IDH-wildtype: transcriptional regulation and inhibition of YB-1 ubiquitination.

AATF supports proliferation of glioblastoma cells by sustaining mitochondrial respiration through an NRF-1-dependent mechanism.

HNRNPH1 drives glioblastoma progression by regulating the splicing of cell cycle genes.

PRDM players in Central Nervous System Cancers: state of the art and future perspectives.

Recent progress and future directions to advance glioblastoma research: A consensus perspective from the 2024 Christopher Davidson Forum.

Molecularly distinct collision tumor consisting of meningothelial meningioma and glioblastoma, IDH-wildtype: illustrative case.

CD47 stabilizes ROBO2 to regulate glioblastoma progression by preventing ITCH-mediated ubiquitination.

Exercise-associated microRNA programs as candidate modulators and biomarkers in glioblastoma: a narrative review.

Biomimetic Nanoplatform for Targeted Glioblastoma Therapy via Concurrently Triggering GPX4/DHODH Mediated Ferroptosis.

Integrative Multi-Omics and Single-Cell Profiling Identify Chitinase Domain Containing Protein 1 (CHID1) as a Prognostic Biomarker in Glioblastoma.

Temporalis Muscle Thickness as a Prognostic Factor for 30-Day, 90-Day, and Overall Mortality in Newly Diagnosed Glioblastoma.

Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies.

Increased expression of SMAD5-AS1 in glioma is associated with patient prognosis and immunity.

Aptamer-functionalized exosomes combined with doxorubicin suppress GBM progression and enhance chemoradiosensitivity by promoting pyroptosis.

Longitudinal, label-free, high-resolution imaging of glioblastoma spheroid response to therapy: a translational tool for preclinical evaluation of chemotherapy, radiation, and immunotherapy.

MEG3 in glioma stem cells promotes glioblastoma angiogenesis through FUBP3-mediated VGF expression.

Plant-derived nanocarriers & nanostructures for barrier-defined translation: a comprehensive review of mechanisms, targets, and translation.

Histogram Analysis of Ultrasound Localization Microscopy for Predicting Isocitrate Dehydrogenase Status in Rat Glioblastoma.

Antitumorigenic activity of Rubus sp. fruit extract in C6 rat and U87 human glioma cell lines.

Recent Development of the Probes for Fluorescence Spectroscopy, Mass Spectrometry and Electron Microscopy in Cancer Diagnosis.

TRIM44 as a Multifunctional Regulator in Cancer and Non-Cancer Diseases: From Oncogenic Driver to Immune and Stress Response Modulator.

Nanotechnology-Based Strategies for Glioblastoma: Diagnostic and Therapeutic Advances.

Glutamate Drives Glioblastoma Invasion in Three-Dimensional Hyaluronic Acid Hydrogels.

Development of Glioblastoma Multiforme in Patients With Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma: A Case Series.

Macrophage membrane-camouflaged nanoparticles for synergistic gene-phototherapy in glioblastoma.

Construction of ammonia death-related lncRNA prognostic signature model and immunomodulatory effect in glioblastoma multiforme.

mRNA-based cancer vaccines: A new frontier in personalized immunotherapy.

The brain imaging feature-related gene NRP2 drives the malignant progression of glioblastoma through the FAK pathway: a Mendelian randomization study.

Finely-tuned regulator of DNA repair: FBXW7-185aa may modulate glioblastoma radiosensitization and the tumor immune microenvironment.

UCHL1 promotes temozolomide resistance in glioblastoma by inhibiting the ubiquitination-mediated degradation of keratin 8.

EZH2 inhibition in resistant glioblastoma stem cells counteracts oxidative stress protection and triggers ferroptosis.

Targeting ULK1 and USP20 to modulate autophagy and chemosensitivity in cancer cell lines.

Combined Patch-clamp Electrophysiology and Single-Cell Genomic Analysis Reveal Spiking Tumor Cells at the Neocortical Glioblastoma Interface in Humans.

CALLY index provides improved prognostic stratification compared with other inflammation-based scores in glioblastoma treated with the stupp protocol.

Reprogramming the immune orchestra for glioblastoma: oncolytic viruses and the B-cell connection.

Exploring the dual role of extracellular vesicles in coagulation and immune modulation in glioblastoma.

ETV1 Promotes Glioma Progression via miR-3175/STEAP2 Axis.

Metabolic Imaging and Molecular Signatures Reveal Metabolic Phenotypes in Recurrent Glioblastoma.

Unraveling the role of boron microdistribution in BNCT dosimetry of glioblastoma multiforme: combined theoretical and experimental insights.

Decoding the biology of the blood-brain tumor barrier in brain cancer.

RAGE Inhibition Reduces Surgery-Induced Cerebral Edema After Glioma Resection.

Discovery, Optimization, and Biological Evaluation of 2-Cyano-2-(9H-xanthen-9-ylidene)acetamide Derivatives as ZNF207 Inhibitors for Anti-Glioma Therapy.

The TNFR superfamily member Fn14 impacts immunity and survival in experimental gliomas and response to immune checkpoint inhibitor therapy in glioblastoma patients.

Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme.

NANP targeting radiosensitizes glioblastoma through TNFR1 sialylation-driven mesenchymal shift.

Celcomen: spatial causal disentanglement for single-cell and tissue perturbation modeling.

Clinical and molecular features of primary gliosarcoma with digital spatial whole-transcriptome analysis of glial and mesenchymal components.

Conditional Survival Estimates for Malignant Glioma Patients: Secondary Analysis of RTOG 9006.

Integrative computational pipeline for the in silico prioritization of potential KIF11-targeting drug candidates in glioblastoma.

A genetically optimized physics-informed neural network for multiphysics modeling of magnetic hyperthermia in brain cancer.

Development and characterisation of a radiobiology proton beamline using radiochromic film dosimetry.

Impact of corticosteroid administration on glioblastoma progression before and after adjuvant treatments: recent updates on contradictory findings and mechanistic interactions.

Antiepileptic drugs in glioblastoma survival: dichotomic or treatment and mechanism of action-dependent variable?

Detecting Extrachromosomal DNA from Routine Histopathology.

Intrinsically disordered SERBP1 regulates translation through topology-driven G-quadruplex recognition.

Aucan targets CDK2 to suppress glioblastoma progression by inhibiting PI3K/AKT pathway-mediated proliferation and inducing apoptosis.

Glioma-induced DNMT3A reduction in microglia promotes an anti-tumoral phenotype.

A blueprint for local and distal invasion programs in glioblastoma.

Glutamate decarboxylase 1 (GAD1) suppresses the progression of glioblastoma through GSK3β/β-catenin pathway.

Synergistic Effects of Curcumin and Temozolomide in Overcoming Glioblastoma Drug Resistance through Regulation of O6-Methylguanine-DNA Methyltransferase, Mismatch Repair, and Poly(Adenosine Diphosphate Ribose) Polymerase 1.

Two translocation mechanisms drive neural stem cell dissemination into the human fetal cortex.

Microglial fructose metabolism is essential for glioblastoma growth.

Synthetic SIGLEC9-based chimeric switch receptor augments the efficacy of CAR macrophages against glioblastoma.

PD-L1 Expression in Gliomas: A Potential Immunotherapeutic Target in High-grade Tumours.

Hybrids of harmine and quinoline-based antimalarials show a strong antiproliferative effect on glioblastoma cells and reverse ATP-binding cassette transporter-mediated drug resistance.

Survival and function in elderly patients with GBM: the role of surgical resection with contemporary multimodal therapy.

Immune checkpoint inhibitors in combination with standard treatment versus standard treatment alone for newly diagnosed glioblastoma: a systematic review and meta-analysis.

Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models.

Peroxidasin promotes malignant progression by enhancing glycolytic metabolism in glioblastoma through the regulation of LDHA.

GlioMODA: Robust glioma segmentation in clinical routine.

Concurrent Ferroptosis and Apoptosis in Resveratrol-Treated Glioblastoma Cells: Relevance With NRF2 Downregulation and Oxidative Stress.

Radiomics-based differentiation between glioblastoma and primary central nervous system lymphoma: CT vs MRI.

tLyP-1 peptide-modified MnO₂ co-delivering si-SLC16A1 and temozolomide synergistically suppresses glioblastoma via hypoxia modulation and metabolic stress.

Pneumocystis jirovecii pneumonia in a chemotherapy-induced immunocompromised patient with glioblastoma multiforme.

Immunotherapy Failure in Glioblastoma: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Syntaphilin inhibits glioma invasion via modulating mitochondria redistribution and shapes the immune microenvironment: A potential prognostic biomarker.

Preclinical validation of tetrahydroquinoline derivatives as EGFR inhibitor inducing glioblastoma cell death.

Bacoside-A enhances temozolomide-induced cytotoxicity in U87MG glioblastoma cells via ROS-mediated apoptosis and EGFR/MAPK inhibition.

Multi-omics analysis identifies CCNB1 as a cell cycle factor driving glioblastoma progression and its inhibition by resveratrol.

Stereotactic Intracranial Implantation of Glioblastoma Patient-derived Xenograft Cell Lines in Mice.

Identification of new prognostic molecular markers in glioblastoma: a single-center retrospective study.

Integrative multi-omics analysis reveals an 11-gene malignant-myeloid interaction signature and identifies TPST1 as a potential regulator of immunosuppressive microenvironment in glioma.

MicroRNAs as diagnostic prognostic and therapeutic biomarkers in glioblastoma.

GPR40 Attenuates Glioma TMZ-Resistance Through Ferroptosis Inhibition.

Framework for statistical parametric mapping of the interactions between glioblastoma location, treatment, prognostic variables, and survival using a phase III trial.

The Size of Glioblastoma Spheroids Influences Patterns of Invasion and Temozolomide Efficacy.

Mismatch repair deficiency reshapes glioblastoma through immune suppression rather than hypermutation.

Enhanced Delivery of Aurora Kinase A Inhibitor Alisertib via Tumor-Targeting Immunoliposome Nanocomplex for Improved Treatment of Cancers Including Atypical Teratoid/Rhabdoid Tumor.

Closing the loop on glioblastoma: A roadmap toward developing bioelectronics for continuous monitoring of tumor state.

Clinical and genetic determinants of glioblastoma survival: a retrospective study.

Adoptive transfer of ILC2s reveals tumor homing in glioblastoma: a proof-of-concept study.

Volumetric MRI-based response assessment and prognostic value in newly diagnosed glioblastoma: RANO 2.0 versus mRANO versus RANO.

Active immunization strategies in glioblastoma - clinical outcomes and effect modifiers for dendritic vaccines and adoptive cell therapies: a systematic review.

Harnessing γδ T cells for B7-H3-targeting CAR therapy to enhance anti-tumor therapy in glioblastoma.

M2-like GAMs secreting CSTA drive glioblastoma progression via the ITGB4-TGFB1 feedback axis.

Disrupting Akt-Wnt/β-catenin signaling suppresses glioblastoma stem cell growth and tumor progression in immunocompetent mice.

Constraints, cumulative doses and toxicity outcomes in glioma reirradiation: a systematic review and radiobiological comparison from the Reirradiation Collaborative Group (ReCog).

Olfactomedin 1 acts as a tumor suppressor in glioblastoma: integrated analysis and mechanistic prediction.

Ferritin in motion: How systemic iron balance and tumor trafficking shape glioblastoma.

Patterns of failure following stereotactic radiosurgery salvage for recurrent high-grade glioma.

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.

Combining Temozolomide with a Selective CK2 Inhibitor Results in Anti-Tumour Effects in Glioblastoma Cell Lines.

Synthesis and Anticancer Evaluation of PCNA Inhibitor AOH1996 Analogs in Cancer Cell Cultures.

Heat up and Destroy: Immunotherapy of "Cold" Tumors Using the Example of Glioblastoma.

TXRF Spectrometry for Investigating CaF2:Nd3+,Y3+ Nanoparticle Diffusion in Tumoral Cancer 3D Spheroids.

AP-2 Transcription Factors as Regulators of Ferroptosis: A Family-Wide Profiling in Diverse Cancer Contexts.

Advancements in Drug Delivery Systems in Glioblastoma Therapy.

Targeting BRD4-A Promising Therapeutic Option for Glioblastoma?

Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.

The Natural Triterpenoid Alisol B Overcomes Temozolomide Resistance in Glioblastoma Through Multi-Target Mechanisms: Coordinated Epigenetic, Metabolic, and Cell-Cycle Reprogramming.

Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens.

Exosome Engineering for Blocking Gut Dysbiosis and Inducing Cell Death Mechanisms in Glioblastoma Multiforme.

Neuro-Oncological Perspectives on Cancer Stem Cell Biology in Glioblastoma: Implications for Resection, Recurrence, Targeted Therapy, and Other CNS Tumors.

MGMT Promoter and Enhancer Methylation in Melanoma Brain Metastases and Glioblastoma: Shared and Distinct Features.

Translating Molecular Insights into Effective Targeting of Glioblastoma Stem Cells.

Resveratrol and AG490 Overcome Glioblastoma Cells' Resistance to Monotherapy by Inhibiting JAK2/STAT3 Signalling Pathway.

Targeted radio-thermo dual sensitizer magnetic gold core-shells nanoparticles enhance radioresistant glioblastoma via promoting apoptosis and ROS generation.

Myeloid-derived immunosuppression of chimeric antigen receptor T cells in the neuronal microenvironment of glioblastoma.

Tumor immunogenicity shapes CNS immune niches and CD8⁺ T cell fate in glioblastoma.

Exploiting Metabolic Dependencies for Therapeutic Targeting of Brain Cancers.

Estimating time-dependent cell survival in particle beam thermoradiotherapy with the dynamic temperature-dependent stochastic microdosimetric kinetic model.

Speech mapping in awake high-grade glioma resection: subcortical tract proximity as a predictor of language outcomes.

Effect of anticancer activity of aripiprazole main metabolite OPC-14857 on malignant glioblastoma.

FET PET Does Not Improve Outcomes Compared with MRI for Re-Irradiation of Recurrent Glioblastoma: GLIAA/NOA-10 ARO2013-01 Trial.

[Retracted] Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine‑γ‑lyase function.

EGFRvIII expression in head and neck squamous cell carcinoma: clinical significance and sources of frequency variation across studies.

Focused ultrasound for blood-brain barrier opening in brain tumor patients: Technical nuances.

Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial.

Assessment of pTERT Subtypes of Glioblastoma by Quantitative FLAIR Analysis Based on Fusing MRI Images.

The lysine methyltransferase KMT5a and p53 regulate the expression of the key autophagy adaptor p62/SQSTM1 in glioblastoma.

Endogenous immune recruitment in glioblastoma CAR T therapy: cytokine, myeloid, and chemokine circuitry.

Metabolic dependencies and neural progenitor dysregulation: driving forces in paediatric high-grade glioma development.

Matrix stress relaxation promotes glioblastoma cell migration in a ligand-specific manner.

A lysosomal requiem for glioblastoma cells.

Eligibility assessment for yttrium-90 radioembolisation in patients with recurrent glioblastoma: A single-centre cohort study based on the FRONTIER clinical trial criteria (NCT05303467).

Synthesis and characterization of new P2X7 receptor antagonists as antitumor agents.

Racial Disparities in Glioblastoma: Can We Untangle Biological From Nonbiological Forces?

USP7 facilitates brain tumor survival upon glucose deprivation by regulating phosphofructokinase muscle-type nuclear translocation in mice.

MGMT downregulation by CRISPR/Cas13 RNA-guided RNA targeting enhances glioma cell sensitivity to TMZ chemotherapy.

Glioma-Immune crosstalk in the tumor microenvironment: mechanistic insights and therapeutic translation.

TERT Promoter Methylation in Glioblastoma and its Paradoxical Association with Upregulated Gene Expression.

A novel mucosa-associated lymphoid tissue translocation gene 1-related immune prognostic signature and targeted drug screening for glioblastoma.

Does coordinated targeting of metabolism and autophagy, modulated by microtubule dynamics, influence therapeutic vulnerability to eribulin in glioblastoma?

[Xihuang Pills induce mitochondria-associated ferroptosis to enhance therapeutic efficacy of temozolomide against glioblastoma via Nrf2/HO-1/GPX4 signaling axis].

Expanding the Inhibitory Potential of the Benzoxaborinine Scaffold against Carbonic Anhydrases: Synthesis, Structural Characterization, and In Vitro Antitumor Activity.

Rapid and sensitive detection of cancer-derived small extracellular vesicles using Janus particles.

Corrigendum to "Nose-to-brain delivery of sorafenib-loaded lipid-based poloxamer-carrageenan nanoemulgel: Formulation and therapeutic investigation in glioblastoma-induced orthotopic rat model" [Int. J. Biol. Macromol. 309 (2025) 142861].

The redox paradox in HGGs: ROS as drivers and destroyers.

Iodinated contrast agents decrease the activity of multidrug resistance protein, cell migration, and induce cell death in different tumor cell lines and glioblastoma spheroids.

A Supportive Group Intervention for Caregivers to Patients Diagnosed With Glioblastoma: Protocol for the SUGRI Study.

Cytoskeletal remodeling promotes tunneling nanotube formation and drives cardiac resident cell mitochondrial transfer in sepsis.

CC8, a heterodimeric disintegrin from Cerastes cerastes snake venom, triggers apoptosis and restrains the dissemination of human glioblastoma cells.

Investigation of the impact of D, L-methadone on ALA-PDT in multiple glioblastoma cell lines.

Socioeconomic disparities in IDH-wildtype glioblastoma survival: interactions between age and household income in a SEER cohort.

A Biomimetic Nanoplatform for Near-Infrared-Assisted Heat-Mediated Synergistic Therapy for Glioblastoma.

The promise and potential of porphyrin metabolite activation using sonodynamic therapy for the treatment of glioblastoma.

Exosomal Lnc-DLK1-35 reprograms microglia into a pro-tumorigenic phenotype via a non-canonical cytokine signature to promote glioblastoma progression and chemoresistance.

Role of human RNase 7 in neuronal and glial cell models: moving towards an unexpected new functional link.

Gliosarcoma: A Reappraisal of Neuroradiological, Surgical, Morphological, and Radiotherapeutic Characteristics of a Cohort From South Italy Single-Center.

Identification of the Antioxidant Enzyme B166 as a Novel Biomarker for Patients With Glioblastoma Multiforme.

Spatial Transcriptomics Meets Histochemistry: Insights from Glioblastoma as a Model System.

Targeting MGAT4A-Mediated N-Glycosylation as a Therapeutic Strategy to Inhibit Glioblastoma Stem Cell Invasion.

The Shifting Prognostic Value of Performance Status in Aging Glioblastoma Patients: A Retrospective Cohort Study.

Brain-targeting nanoplatform repurposing silymarin for enhanced GBM immunotherapy via synergistic mitochondrial suppression.

Recurrent Glioblastoma and the Tumor Immune Landscape: Emerging Immunotherapeutic Strategies.

miR-181d coordinates homologous recombination and anti-tumor immune responses in glioblastoma.

Endoscopic Transorbital Approach for Select Recurrent and Newly Diagnosed Anteromedial Temporal Lobe Gliomas.

A Brain-Targeting Curcumin Analog Inhibits Glioblastoma Progression Through THBS1/TGF-β1/PI3K-AKT Axis Modulation: Evidence From Experimental and Bioinformatic Analyses.

Evolving landscape of glioblastoma research : A 75-year bibliometric study on survival, treatment and gender in authorship.

Pan-cancer analysis of NTRK2 (TRKB) and the anticancer effect of its inhibitor Lucitanib in glioma.

Glioblastoma survival in rural America: a 10-year experience from a quaternary care center.

First-in-Class Small Molecule Inhibitor of Oncogene AVIL in Glioblastoma.

Porous organosilica nanoparticles enable UV blocking and two-photon fluorescence imaging.

Radiomics in glioblastoma recurrence: advances in prediction, localization, and differentiation from treatment-related effects.

Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma.

DLD, upregulated by YY1, fuels glioblastoma multiforme progression via EphA2 phosphorylation to activate PI3K/AKT/mTOR.

Dual role of LY96 in shaping the mesenchymal glioblastoma ecosystem through stem cell maintenance and macrophage MES-like reprogramming.

Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.

Investigation of the impact of resveratrol on sublethal-dose ALA-PDT in glioblastoma cells.

Formyl Peptide Receptor-2-Suppressed Autophagy Promotes the Migration and Invasion of Human Glioblastoma Cells Through PI3K/Akt Signaling.

Neurosurgical leadership in neuro-oncology clinical trials: A nationwide study.

Survival and prediction of distant recurrence in glioblastoma.

Progress in the research and development of oncolytic virus therapies.

[64Cu]Cu-Labeled αCD11b Diabody as a Novel PET Tracer for the Detection of Immunosuppression in Glioblastoma.

High-grade gliomas and Lynch syndrome: A retrospective descriptive study with a literature review.

Health-related quality of life outcomes of surgery for diffuse glioma: A systematic review and pooled analysis.

Gliosarcoma of the right cerebellar hemisphere and parahippocampal region: A case report and literature review.

IGF2BP3-GP130-STAT3-WTAP loop promotes the malignant progression in glioblastoma.

DENND2D serves as a novel prognostic biomarker with paradoxical protumorigenic effects in glioma.

Comprehensive analysis of the potential role of Ferroptosis-related genes in glioblastoma multiforme.

Electrochemically optimized multi-component polyacrylonitrile nanofiber scaffolds as a platform for three-dimensional glioblastoma cell culture.

L1CAM Promotes the Infiltrative Properties of Patient-Derived Glioblastoma Cells.

A near-infrared fluorescent probe for HClO detection and image-guided surgery in glioblastoma.

Machine learning model on multi-omics data enables risk stratification and identifies molecular heterogeneity and therapeutic targets in glioblastoma.